Mineralys Therapeutics, Inc.’s Post

Are you using your existing investors to sharpen your pitch skills before you head out to raise your round? If not, you're missing a trick....join Uzma Choudry, Ph.D and I as we discuss this and much more on the latest episode of our brand new podcast, The Other Side of The Table. Listen now at https://lnkd.in/eyx2Csmq #biotechnology #biotech #techbio #lifesciences #healthtech #podcast #newpodcast #venturecapital #vc #vcfunding #seriesa #investorinsights #seriesb

Our Chief Business Officer Stephanie A. Sirota recently sat down with Labiotech.eu’s Beyond Biotech Podcast to discuss the evolution of RTW’s research-driven approach over the last 15 years, the incredible innovation taking place in medicine, and why the firm is excited about the outlook of the biotech market in 2024 and beyond.   You can listen to the full episode here, as well as on most podcast platforms: https://lnkd.in/eAGaEgPY   #lifesciences #biotech #investing #markets #podcast

🧑🔬 Looking to build your biotech team? 💊 Want to create something that will actually have a positive impact? Well luckily for you, we’ve got you covered 😉 The latest episode of Building Biotechs: A Podcast by Recruitomics Consulting is out now! 🎧 We’re joined by Nathalya Mamane, CEO & Founder of RT MicroDx to discuss how she combined her business acumen with her need to create an impact, as well as the future of home testing kits…   Click the link in the comments to listen to the full episode (and remember to subscribe!) 👇 #biotech #hometestingkits #buildingbiotechs

This week, Brian Finrow joins the #businessofbiotech for a candid conversation on the advantages--and the disadvantages--of being a #biotech "outsider." His company, Lumen Bioscience, doesn't do #antibody science the old-fashioned way, and as a result, it doesn't raise funds the old-fashioned way, either. Finrow's perspective is an honest and refreshing one, and Lumen's story of novelty, grit, and success proves that true innovation isn't bred by the way it's always been done. Watch the full episode here, or listen in anywhere you subcribe to podcasts. https://lnkd.in/gXZhFj85

In this episode of the #TDCowen Biotech Decoded podcast, Arsani William, MD of Logos Global Management, LP joins Yaron Werber to discuss what's on the horizon for #Biotech. https://go.td.com/4cPF2fX #TDCowenHealthCare

Our podcast, Biotech Insiders, is about to record episode 4, if you are interested in sponsoring, please contact me. Our next episode has two great guests and an impactful student segment. If you want to reach our network, sponsorship on the podcast is a great way to do so. Thanks much! #biotechnology #innovation #stemeducation

Good insight. Worth listening and subscribing.

Financial and Technical Aspects Driving Today’s Life Sciences Deal Making: Listen to PharmaVentures’ latest podcast. Click here: https://bit.ly/PVPodcast11 Andrew G. gives key insight into the deal making landscape - asset value, accessing the market, positioning and the actual deal process in the current economic climate - from the unique position standing astride both the financial world and the technical world translating science into value. The podcast is hosted by Adrian Dawkes. #pharmaceuticalindustry #biotech #pharma #investment #partnering #innovation #funding #dealmaking #consulting #lifesciences #Sachs_HTIF #commercialstrategy #benchmarking #assetvaluation #mergersandacquisitions  #divestment #podcast #TheDealExperts

New podcast just dropped! In our podcast series "The World in A Grain of Sand", we break down an S1 from a recent biotech IPO and share insights on the science, R&D, business models, financials, and more. In this episode, KdT Ventures Partners Cain McClary, MD and Mack Healy take a deep dive into a biotech firm that owns a piece ~25% (!) of all blockbuster drugs - Royalty Pharma. In this episode, we cover: - an overview of Royalty Pharma's investment model, and how they generate cash flow from ~25% of all blockbuster drugs - growth strategies in the face of increased competition and a challenging macro environment - the bull and bear case for Royalty Pharma Listen here, and if you enjoy it, please subscribe, comment, and share with your friends: Apple Podcasts: https://lnkd.in/gx7aZ-9T Spotify: https://lnkd.in/gSe9MvDk #podcast #biotech #pharma #venturecapital

What is single-cell RaCH-seq? Learn about the single-cell technique in our latest podcast episode with Rachel Thijssen, in partnership with Oxford Nanopore Technologies. Check it out >>> https://bit.ly/3u6IEcq